Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial

BACKGROUND: A proposed cause of dyspnea induced by ticagrelor is an increase in adenosine blood levels. Because caffeine is an adenosine antagonist, it can potentially improve drug tolerability with regard to dyspnea. Furthermore, association between caffeine and cardiovascular events is of clinical...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Am Heart Assoc
Päätekijät: Furtado, Remo H. M., Venkateswaran, Ramkumar V., Nicolau, Jose C., Gurmu, Yared, Bhatt, Deepak L., Storey, Robert F., Steg, P. Gabriel, Magnani, Giuglia, Goto, Shinya, Dellborg, Mikael, Kamensky, Gabriel, Isaza, Daniel, Aylward, Philip, Johanson, Per, Bonaca, Marc P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7660882/
https://ncbi.nlm.nih.gov/pubmed/32410485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.015785
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia